“From an operational perspective this deal will allow Sensyne to scale its business more quickly, reduce its need to expand the internal employee base to deliver some key systems and importantly, give it expertise in some areas it would otherwise have to take time to build itself.
“Strategically the deal is very interesting in two ways. Firstly, Microsoft works with a number of leading pharma companies that could be significant potential clients for Sensyne’s Discovery Sciences business, including a particularly strong relationship with Novartis.
“Secondly, Microsoft already works closely with Cognizant in digital healthcare and we believe this deal will help to create a tripartite entity with each bringing a unique capability to the table – we believe Microsoft and Cognizant have chosen Sensyne as their partner for data driven insights in healthcare.”
Sensyne had announced earlier today that it would work with Microsoft on clinical AI and health cloud technologies.
Practically, the enhanced tie-up is set to deliver the latest ‘cloud-first’ healthcare systems and cutting-edge predictive machine learning algorithms.
With Microsoft’s help, Sensyne said it aims to create “highly configurable” healthcare technologies that are globally deployable and able to meet local, clinical and regulatory needs.
Sensyne chief executive Lord Drayson said: “This strategic partnership with Microsoft will further enhance Sensyne’s ability to advance and scale the benefits that advanced clinical AI can bring to improve patient outcomes and accelerate the development of new medicines through its research partnerships with NHS Trusts.”
Shares in Sensyne jumped 10% to 116.5p, Liberum has a ‘buy’ rating and 260p price target.